Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Marbelle Threads Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, ARNOLD, ERNST V, who is also identified as the busiest examiner for the portfolio. The concentration of work under 1 distinct art unit suggests a focused prosecution strategy within a specific technical niche. Because the busiest examiner handles 1 busiest examiner pending action, the firm's immediate patent outcomes depend on this individual's review.
The presence of 1 pending office action across 1 distinct examiner indicates a portfolio of limited size at the USPTO. Practitioners should note that with 1 distinct art unit involved, there is no diversification of examination styles or departmental norms. This streamlined structure allows for a direct response strategy tailored to the specific preferences of ARNOLD, ERNST V. The current workload represents a singular focus for the company in this sector, requiring a precise and technically grounded response to the pending matter. This concentration of resources under a single examiner and art unit simplifies the administrative tracking of the application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18772596 | THREADS OF CROSS-LINKED HYALURONIC ACID AND HYDROXYAPATITE | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18772596 | THREADS OF CROSS-LINKED HYALURONIC ACID AND HYDROXYAPATITE | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | — | Pending | Jul 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial